Adenocystic Carcinoma
Conditions
Keywords
cephalic and cervical adenocystic Carcinoma, Chidamide
Brief summary
The purpose of this trial is to evaluate the efficiency and safety of Chidamide in advanced cephalic and cervical adenoid cystic carcinoma. Chidamide is given to patients with advanced cephalic and cervical adenoid cystic carcinoma with the dosage of 30mg,twice a week, then overall survival, event-free survival are accessed for efficiency, and laboratory tests about the function of vital organs are accessed for safety.
Interventions
DRUGChidamide
Sponsors
Dong mei
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients of advanced cephalic and cervical adenocystic carcinoma with pathological and imaging evidences, with local relapse or metastasis or refractory towards treatment. 2. Age 18-75, male or female, expected survival≥ 3 months. 3. ECOG 0-2. 4. With at least one evaluable disease focus. 5. Organ functions should fit the following: Liver: Total bilirubin ≤ 1.5 times of the normal maximum, ALT and AST≤ 2.5 times of the normal maximum. (ALT/AST≤ 5 times of the normal maximum for patients with infiltrative liver disease) Kidney: Serum creatinine ˂ 1.5 folds of the normal maximum; creatinine clearance rate ≥50ml/min (calculated by Cockroft-Gault10 formula)
Exclusion criteria
1. History of HDACI treatment. 2. Women during pregnancy or lactation. 3. Patients with a second primary tumor ( this does not include non-melanoma skin cancer received systemic treatment, cured cervical carcinoma in situ of the uterus, or other tumors that have been cured with disease free survival˃ 5 years) 4. Patients with central nervous system defects or mental disorders. 5. Other diseases or contraindications: History of heart disease within 6 months prior to inclusion, including NYHA III-IV heart failure after treatment, coronary heart disease, angina pectoris, myocardial infarction, degree II or III atrioventricular block, severe arrhythmias that need medical treatment, uncontrolled hypertension; liver cirrhosis (Child-Pugh B or C); active infection that has not been controlled, and other conditions that may make the patient unable to complete the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate | through study completion, an average of 33 months | percentage of patients who get complete remission, partial remission and stable disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicities | every 3 weeks though study completion，from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months | Hematologic toxicities and non-hematologic toxicities including nausea，vomiting，liver, heart and other organ disfunctions. |
| QOL score | every 3 weeks though study completion，from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months | improvement of patients' feeling and quality of daily life |
Countries
China
Contacts
Primary ContactMei Dong, Doctor
Outcome results
None listed